Who are Pathogen-Reduced Cryoprecipitate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): FFP and Cryoprecipitate, FFP/Cryo, Freezed-dried plasma.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pathogen-reduced-cryoprecipitate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pathogen-Reduced Cryoprecipitate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pathogen-Reduced Cryoprecipitate (Pathogen-Reduced Cryoprecipitate) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Blood product / Hemostatic agent. Area: Hematology / Hemostasis.

marketed Blood product / Hemostatic agent Hematology / Hemostasis Biologic Live · refreshed every 30 min

Target snapshot

Pathogen-Reduced Cryoprecipitate (Pathogen-Reduced Cryoprecipitate) — Weill Medical College of Cornell University. Pathogen-reduced cryoprecipitate is a blood product containing fibrinogen, von Willebrand factor, fibronectin, and other clotting factors that have been treated to inactivate pathogens while preserving hemostatic function.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Pathogen-Reduced Cryoprecipitate TARGET	Pathogen-Reduced Cryoprecipitate	Weill Medical College of Cornell University	marketed	Blood product / Hemostatic agent
FFP and Cryoprecipitate	FFP and Cryoprecipitate	The University of Texas Health Science Center, Houston	marketed	Blood product / Hemostatic agent
FFP/Cryo	FFP/Cryo	Biotest	phase 3	Blood product / Hemostatic agent
Freezed-dried plasma	Freezed-dried plasma	University Hospital, Lille	phase 3	Blood product / Hemostatic agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Blood product / Hemostatic agent class)

Biotest · 1 drug in this class
The University of Texas Health Science Center, Houston · 1 drug in this class
University Hospital, Lille · 1 drug in this class
Weill Medical College of Cornell University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pathogen-Reduced Cryoprecipitate — Competitive Intelligence Brief. https://druglandscape.com/ci/pathogen-reduced-cryoprecipitate. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing